Tiziana Life Sciences Ltd TLSA

Company Overview

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on the development of immunomodulatory therapies for neurodegenerative, autoimmune, and inflammatory diseases. The company operates within the biopharmaceutical and life sciences industry, with its core value derived from advancing novel biologic candidates through clinical development rather than commercialized products. As of the most recent public disclosures, the company does not generate material product revenue and relies primarily on capital markets to fund operations.

The company’s primary asset and revenue driver in development is foralumab, a fully human anti-CD3 monoclonal antibody designed for intranasal and oral administration, which differentiates it from traditional intravenous anti-CD3 therapies. Tiziana Life Sciences was founded in 2013 and has evolved from a broader life sciences holding company into a more focused clinical-stage immunology company. It is incorporated in the United Kingdom and its ordinary shares are listed on the NASDAQ Capital Market under the ticker TLSA, reflecting its strategic emphasis on access to U.S. capital markets.